Health Care & Life Sciences » Biotechnology | Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
30.17 M
Public Float
28.59 M
Conatus Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
$0.57
Market Cap
$10.18 M
Shares Outstanding
33.17 M
Public Float
26.16 M

Profile

Address
16745 West Bernardo Drive
San Diego California 92127
United States
Employees -
Website http://www.conatuspharma.com
Updated 07/08/2019
Conatus Pharmaceuticals, Inc. engages in the development and commercialization of medicines for the treatment of liver diseases. It focuses in development of emricasan, an active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease, which reduce the activities of human caspases. The company was founded by Alfred P.

Financials

View All

Steven J. Mento
President, Chief Executive Officer & Director
David F. Hale
Chairman